ALLR · Allarity Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.30M | - | $1.20M | $2.32M | $1.40M | - | $1.02M | $1.06M | $2.17M | - |
| SG&A | $1.42M | - | $1.31M | $1.81M | $1.63M | - | $1.59M | $2.31M | $2.07M | - |
| Total Operating Expenses | $2.71M | - | $2.52M | $4.13M | $3.04M | - | $12.31M | $3.37M | $4.24M | - |
| D&A | - | - | - | - | $2.0K | - | - | - | $2.0K | - |
| Operating Income | ($2.69M) | - | ($2.52M) | ($4.13M) | ($3.04M) | - | ($12.31M) | ($3.37M) | ($4.24M) | - |
| Interest Expense | $229.0K | - | $57.0K | $12.0K | $102.0K | - | $34.0K | $426.0K | $102.0K | - |
| Income Tax | - | - | $0 | $0 | $0 | - | ($377.0K) | - | ($4.0K) | - |
| Net Income | ($2.75M) | - | ($2.81M) | ($2.32M) | ($2.73M) | - | ($11.59M) | ($1.63M) | ($3.84M) | - |
| EPS - Basic | ($0.17) | - | ($0.19) | ($0.15) | ($0.25) | - | ($7.71) | ($0.11) | ($22.14) | - |
| EPS - Diluted | - | - | - | - | - | - | - | ($0.11) | ($22.14) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.81M | $14.69M | $16.89M | $17.80M | $25.20M | $19.53M | $18.50M | $19.23M | $295.0K | $166.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.24M | $4.28M | $4.60M | $4.61M | $4.35M | $4.18M | $4.69M | $7.75M | $11.06M | $8.42M |
| Current Assets | $34.50M | $17.93M | $20.47M | $20.88M | $29.42M | $22.34M | $20.37M | $21.31M | $2.29M | $1.97M |
| Total Assets | $34.92M | $18.26M | $20.80M | $21.20M | $29.73M | $22.65M | $20.38M | $30.88M | $11.97M | $11.86M |
| Current Liabilities | $28.00M | $8.43M | $8.79M | $9.04M | $11.06M | $10.84M | $7.41M | $10.62M | $18.01M | $14.17M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $2.69M |
| Total Liabilities | $28.00M | $8.43M | $8.79M | $9.04M | $11.06M | $10.84M | $7.41M | $11.05M | $18.44M | $14.61M |
| Stockholders' Equity | $6.92M | $9.83M | $12.01M | $12.17M | $18.67M | $11.81M | $12.96M | $19.84M | ($6.47M) | ($2.75M) |
| Retained Earnings | ($132.95M) | ($130.20M) | ($126.82M) | ($124.02M) | ($121.70M) | ($118.97M) | ($111.51M) | ($99.92M) | ($98.29M) | ($94.45M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.49M) | - | - | - | ($2.69M) | - | - | - | ($1.49M) | - |
| Investing Cash Flow | $0 | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $19.74M | - | - | - | $11.14M | - | - | - | $1.38M | - |
| CapEx | $64.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($4.56M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.66 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.9% | - | -13.5% | -10.9% | -9.2% | - | -56.9% | -5.3% | -32.1% | - |
| Return on equity | -39.7% | - | -23.4% | -19.1% | -14.6% | - | -89.4% | -8.2% | 59.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.23 | 2.13 | 2.33 | 2.31 | 2.66 | 2.06 | 2.75 | 2.01 | 0.13 | 0.14 |
| Quick ratio | 1.23 | 2.13 | 2.33 | 2.31 | 2.66 | 2.06 | 2.75 | 2.01 | 0.13 | 0.14 |
| Cash ratio | 0.71 | 1.74 | 1.92 | 1.97 | 2.28 | 1.80 | 2.50 | 1.81 | 0.02 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | -0.98 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.23 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -11.7x | - | -44.2x | -344.4x | -29.8x | - | -362.1x | -7.9x | -41.6x | - |
| Equity multiplier | 5.05 | 1.86 | 1.73 | 1.74 | 1.59 | 1.92 | 1.57 | 1.56 | -1.85 | -4.31 |
| Liabilities / Assets | 0.80 | 0.46 | 0.42 | 0.43 | 0.37 | 0.48 | 0.36 | 0.36 | 1.54 | 1.23 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 11.5% | - | 79.6% | -22.6% | 28.4% | - | -178.2% | 18.9% | -15.9% | - |
| Net income growth (YoY) | -0.7% | - | 75.8% | -42.4% | 28.9% | - | -160.6% | 31.6% | -14.6% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | 99.6% | -399.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.9% | -16.8% | -7.4% | -38.7% | - | - | - | - | -108.6% | -2334.5% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Allarity Therapeutics against the 5 most active filers in the same SIC group.